An interventional study of Paliperidone Palmitate Injection (3M) in Schizophrenia, sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-25.
Sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.
Among the 115 studies testing paliperidone in Schizophrenia, this one is the 42nd largest by planned enrollment, is the only one that started in 2024, is one of 4 with no phase, and was the 114th registered.
3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.
Browse Schizophrenia studies →6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
Alejandro Alva · Sites in United States
Ages 18–65
Jiangsu Province Nanjing Brain Hospital · Sites in China
Ages 18–65
Sher-E-Bangla Medical College · Sites in Bangladesh
Ages 18–60
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Ages 15–40
By country, each count listing its studies:
paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 7 · Phase 3 42 · Phase 4 42
First in 2003; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 260 is above the median of 70 across 2,953 interventional studies indexed under Schizophrenia.
Median enrollment 178 across the 115 interventional studies. Of the 104 that completed or were terminated, 42 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
93 of 115 have an industry lead sponsor. The 10 most frequent:
This study is registered under CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., one of the names counted as CSPC Pharmaceutical Group Limited. Under that name alone:
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. is the lead sponsor of 30 studies on the registry; 21 are open to participants now.
CSPC Pharmaceutical Group Limited has 4 studies filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
2 of the studies testing paliperidone in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07493551CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.A Bioequivalence Study of PP3M in Patients With Schizophrenia | 2026-12-31 |
| NCT04478838Centre for Addiction and Mental Health"Extended" (Alternate Day) Antipsychotic Dosing | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 115 studies testing paliperidone in Schizophrenia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the bioequivalence of the test formulation paliperidone palmitate injection (3M) produced by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. and the reference formulation paliperidone palmitate injection (3M) (brand name: Invega Trinza) by Janssen Pharmaceutica N.V. under multiple-dose administration.
A randomized, open-label, multi-center, two-drug, multiple-dose, parallel-design study was conducted among patients with schizophrenia in China to evaluate the bioequivalence of the test formulation paliperidone palmitate (3M) produced by CSPC zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. and the reference formulation paliperidone palmitate injection (3M) (trade name: Santodar) of Janssen Pharmaceutica N.V.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Paliperidone Palmitate Injection (3M), 1.75 mL: 350 mg
Drug: Paliperidone Palmitate Injection (3M)
Invega Trinza, 1.75 mL: 350 mg
Drug: Paliperidone Palmitate Injection (3M)
Intramuscular injection
Also known as: SYHF2037
Cmax,ss,
Maximum plasma concentration at steady state
Time frame: Up to Day456
AUCτ,ss
Area under the plasma concentration-time curve over a dosing interval at steady state
Time frame: Up to Day456
Title:Incidence and severity of adverse events (AEs)
The frequency and degree of harmfulness of adverse events
Time frame: Up to Day456
Started Oct 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.
Of 775 interventional studies with no phase under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 56. This study's planned 26 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Paliperidone
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. →